Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;37(8):2421-2423.
doi: 10.1007/s40620-024-02005-7. Epub 2024 Jul 16.

Efficacy and safety of switching from Eculizumab to Ravulizumab for the maintenance of aHUS remission after kidney transplant: a preliminary experience

Marco Busutti #  1 , Federica Maritati #  1 , Greta Borelli  1 , Claudia Bini  1 , Valeria Corradetti  1 , Vania Cuna  1 , Chiara Abenavoli  1   2 , Michele Provenzano  1   2 , Matteo Ravaioli  2   3 , Gaetano La Manna  4   5 , Giorgia Comai  1   2
Affiliations

Efficacy and safety of switching from Eculizumab to Ravulizumab for the maintenance of aHUS remission after kidney transplant: a preliminary experience

Marco Busutti et al. J Nephrol. 2024 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors have nothing to disclose. Ethical approval: The study was conducted in accordance with the standards as laid down in the in the 1964 Declaration of Helsinki and its later amendments, and was approved by IRCCS AOU Bologna Ethics Committee (cod. 586/2023/Oss/AOUBo). Ethical approval was waived by the local Ethics Committee of University of Bologna, in view of the retrospective nature of the study and all the procedures being performed were part of the routine care. Informed consent: Patients gave informed consent for publication of their data.

References

    1. Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon SS, Kavanagh D, Haller H (2021) The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int 97(6):1287–1296 10.1016/j.kint.2020.01.035(Epub 2020 Mar 6. Erratum in: Kidney Int 98(6):1621. Erratum in: Kidney Int 99(5):1244 PMID: 32299680) - PubMed
    1. Sheridan D, Yu ZX, Zhang Y, Patel R, Sun F, Lasaro MA, Bouchard K, Andrien B, Marozsan A, Wang Y, Tamburini P (2018) Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS ONE 13(4):e0195909. 10.1371/journal.pone.0195909 - PMC - PubMed
    1. Gonzalez Suarez ML, Thongprayoon C, Mao MA, Leeaphorn N, Bathini T, Cheungpasitporn W (2019) Outcomes of kidney transplant patients with atypical hemolytic uremic syndrome treated with eculizumab: a systematic review and meta-analysis. J Clin Med 8(7):919. 10.3390/jcm8070919 - PMC - PubMed
    1. Maritati F, Corradetti V, Bini C, Provenzano M, Cuna V, Busutti M, Tondolo F, Zappulo F, Vischini G, Iacovella F, Abenavoli C, Borelli G, Demetri M, Fabbrizio B, Radi G, Ravaioli M, Mele C, La Manna G, Comai G (2024) Eculizumab first in the management of posttransplant thrombotic microangiopathy. Kidney Int Rep 9:982–993 - PMC - PubMed
    1. Barbour T, Scully M, Ariceta G, Cataland S, Garlo K, Heyne N, Luque Y, Menne J, Miyakawa Y, Yoon SS, Kavanagh D, 311 Study Group Members (2021) Long-term efficacy and safety of the long-acting complement C5 inhibitor ravulizumab for the treatment of atypical hemolytic uremic syndrome in adults. Kidney Int Rep 6(6):1603–1613. 10.1016/j.ekir.2021.03.884 - PMC - PubMed

LinkOut - more resources